Back

Cardiac resynchronization therapy, remodeling and outcome in patients with amyloid transthyretin cardiomyopathy

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Prognostication and treatment of transthyretin cardiac amyloidosis Infiltrative Myocardial Disease ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Alberto Aimo

Sant'Anna School of Advanced Studies, Pisa (Italy)

7 More presentations in this session

Presentation thumbnail
When to stop? Real-world decision pathways for transthyretin stabilizer discontinuation in cardiac amyloidosis
Doctor K. Knoll (Munich, DE)
Abstract Slides Video
Presentation thumbnail
Impaired right ventricular free wall strain predicts mortality in patients with stabilizer-treated transthyretin amyloid cardiomyopathy.
Doctor S. Schwarting (Munich, DE)
Abstract Slides Video
Presentation thumbnail
Distribution and prognostic impact of left and right systolic and diastolic functions in wild-type transthyretin amyloid cardiomyopathy
Doctor A. Mejren (Aarhus, DK)
Abstract Slides Video
Presentation thumbnail
Identifying predictors and cutoff values for pacemaker implantation in ATTR patients
Doctor S. Istratoaie (Cluj Napoca, RO)
Abstract Slides Video
Presentation thumbnail
Survival in a contemporary, real-world, matched cohort of patients with transthyretin amyloid cardiomyopathy treated vs not treated with tafamidis
Doctor M. Hanna (Cleveland, US)
Abstract Slides Video

Access the full session

Session thumbnail
Prognostication and treatment of transthyretin cardiac amyloidosis

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Cardiac resynchronization therapy, remodeling and outcome in patients with amyloid transthyretin cardiomyopathy
thumbnail
Congress Presentation
Clinical implications of cardiac implantable electronic devices in ATTR cardiomyopathy
thumbnail
Congress Presentation
Conventional medical therapies in patients with heart failure across different risk for transthyretin amyloid cardiomyopathy in the DELIVER, PARAGON-HF and TOPCAT Americas trials

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources